U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
On Monday, Leerink Partners maintained a positive outlook on Biohaven Pharmaceutical Holding (NYSE:BHVN), reiterating an Outperform rating and a $60.00 price target for the company's stock. This affirmation comes in light of recent Phase 3 data from a competitor that may have favorable implications for Biohaven's own upcoming trial results.
The recent Phase 3 SAPPHIRE trial data for a spinal muscular atrophy (SMA) treatment from Scholar Rock showed promising results, which Leerink Partners believes could bode well for Biohaven's Phase 3 RESILIENT trial of taldefgrobep alfa (T-alfa). T-alfa is an adnectin that inhibits both myostatin and activin A pathways, and its Phase 3 trial results are anticipated in the second half of 2024.
Leerink Partners highlighted the differences between the two drugs, noting that although there are variations in the clinical endpoints, the duration on background standard of care therapies, and trial populations, the positive data from Scholar Rock's trial provides the first strong placebo-controlled clinical validation of this mechanism of action in SMA and demonstrates a proof of gain of motor function in SMA patients.
In addition, Leerink Partners mentioned another competitor, Hansa, which released positive data from its IgG degrader that targets myasthenia gravis flares and acute attacks in other autoimmune disorders. Despite the crowded space, the firm expressed continued confidence in the potential market opportunity for degraders in various indications and anticipates further updates in the second half of 2024 and the first half of 2025.
Leerink Partners concluded by reinforcing their positive stance on Biohaven's stock, stating that they now assume there is at least a $4 increase in the stock price factored in for the upcoming trial of T-alfa in SMA. The firm remains optimistic about the risk-reward profile for Biohaven as they await the RESILIENT trial results.
In other recent news, Biohaven Pharmaceutical Holding has been making significant strides with its drug development programs. The company's drug, troriluzole, showed positive results in clinical trials for Spinocerebellar Ataxia (SCA), potentially slowing disease progression by 50-70%. Analysts suggest that if approved, troriluzole could achieve peak U.S. sales of over $1.5 billion. Additionally, Biohaven has initiated a public offering of its common shares, potentially reaching gross proceeds of approximately $250 million.
The company has also launched a pivotal Phase 2 study for its new migraine treatment, BHV-2100, after encouraging results in Phase 1 trials. Furthermore, Biohaven plans to file for approval for its lead candidate, BHV-1300, following FDA approval for Multiple Ascending Dose studies in Rheumatoid Arthritis patients.
Various analyst firms such as Leerink Partners, H.C. Wainwright, BofA Securities, and TD Cowen have acknowledged these advancements, maintaining positive ratings and increasing their price targets for Biohaven.
InvestingPro Insights
To complement Leerink Partners' optimistic outlook on Biohaven Pharmaceutical Holding (NYSE:BHVN), recent data from InvestingPro offers additional context for investors. Despite the company's current lack of profitability, with a negative P/E ratio of -6.3 over the last twelve months as of Q2 2024, BHVN has demonstrated remarkable market performance. The stock has seen a strong 29.08% return over the past month and an impressive 98.29% return over the last year, suggesting investor confidence in the company's potential.
InvestingPro Tips highlight that Biohaven holds more cash than debt on its balance sheet, which could provide financial flexibility as the company awaits critical trial results. This solid cash position aligns with the anticipation surrounding the upcoming RESILIENT trial results for taldefgrobep alfa.
It's worth noting that analysts do not anticipate the company to be profitable this year, which is consistent with the developmental stage of its key drug candidates. However, the stock's volatility and high returns over various periods reflect the market's reaction to clinical trial news and potential breakthroughs in Biohaven's pipeline.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide deeper insights into Biohaven's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.